Viral Genetics Completes Patient Enrollment for South African VGV-1 Trial

Viral Genetics has completed patient enrollment in its South African Phase III trial of VGV-1 for the treatment of HIV-1.

VGV-1 has demonstrated safety in previous human clinical trials and is believed to suppress HIV-1 viral load in patients. The primary endpoint of this trial is the effect of VGV-1 on the amount of virus in the blood or viral load.

Prior to the initiation of the trial, the Medicines Control Council of South Africa approved and designated the study, "Phase III Assessment of Safety and Efficacy of Thymus Nuclear Protein Injections for treating stage CDC-2 HIV-1 infected patients." The primary goal of the study is to monitor the safety, efficacy and immunological function of VGV-1. The study design involves treatments of VGV- 1 or placebo for 51 days with 240 days of follow-up.

Originally, Viral Genetics had planned to enroll 80 patients in the trial but increased the number to 135 after the addition of two additional trial sites. The company may add additional patients subject to pending pre-enrollment screening.